CBS 2019
CBSMD教育中心
English

动脉粥样硬化性心血管疾病预防

科研文章

荐读文献

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women: JACC State-of-the-Art Review High-Risk Coronary Plaque Regression After Intensive Lifestyle Intervention in Nonbstructive Coronary Disease: A Randomized Study 2019 ACC/AHA/ASE Advanced Training Statement on Echocardiography (Revision of the 2003 ACC/AHA Clinical Competence Statement on Echocardiography): A Report of the ACC Competency Management Committee Long-term effects of intensive glucose lowering on cardiovascular outcomes Association of Circulating Monocyte Chemoattractant Protein-1 Levels With Cardiovascular Mortality: A Meta-analysis of Population-Based Studies Primary Prevention Trial Designs Using Coronary Imaging: A National Heart, Lung, and Blood Institute Workshop Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes Short-Term Progression of Multiterritorial Subclinical Atherosclerosis Negative Risk Markers for Cardiovascular Events in the Elderly

Guideline31 August 2019

JOURNAL:Eur Heart J. Article Link

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)

F Mach, C Baigent, ESC Scientific Document Group et al. Keywords: Guidelines; dyslipidaemias; cholesterol; triglycerides; low-density lipoproteins; high-density lipoproteins; apolipoprotein B; lipoprotein(a); lipoprotein remnants; total cardiovascular risk; treatment (lifestyle); treatment (drugs); treatment (adherence); very low-density lipoproteins; familial hypercholesterolaemia

FULL TEXT PDF